tak-593
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2009 (NCT00773929)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Platelet-derived growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C(=O)Nc2cc(Oc3ccc4nc(NC(=O)C5CC5)cn4n3)ccc2C)n(C)n1- Mol. weight
- 445.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2180604 ↗
Also known as
- tak593
- tak 593
- tak-593
- tak-593
- tak-593
- tak-593
- tak-593
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00773929 | Phase 1 | Jan 1, 2009 | Millennium Pharmaceuticals |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals | For profit | 1 | 1 | 1 | 2009 |
1 organizations
Page 1 / 1